**Supplementary Table 6.** Outcome of studies using the Modified Ficat Classification

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Nr.** | **Avg. Follow-up** | **Preoperative Staging** | **Clinical assessment tool** | **Postoperative Clinical improvement** | **Time to clinical deterioration (Avg, months)** | **Radiographic success (no progression)** | **Time to THR, months (% of total hips)** |
| Abrisham 2013[25] | 37 | 24 | Stage I – 27%Stage IIA – 73% | n/a | n/a | n/a | 25% - no progressionStage I – 0%Stage IIA – 48.1% | n/a |
| Bozic 1999[31] | 54 | 120 | Stage I: 24%Stage IIA: 42.5%Stage IIB: 18.5%Stage III: 14.8% | n/a | Overall 48%Stage I: 92%Stage IIA: 52%Stage IIB: 20%Stage III: 0% | 97 M | (% out of FICAT Pre-Op Sub-groups):Stage I: 69.2%Stage IIA: 43.4%Stage IIB: 10%Stage III: 0% | 22 M (63%) |
| Kang 2011[44] | 60 | 63 | Stage IIA: 28.9%Stage IIB: 46.1%Stage III: 25% | HHS | 71.2% | 81.3 M | 67.4% | 62.5 (overall - 28.8%;Stage II - 21%;Stage III - 54%) |
| Lakshminarayana 2019[47] | 36 | 54 | Stage I : 100% | HHS VAS | HHS – YES;VAS - YES | n/a | 75% (9/36 showed radiographic progression) | n/a |
| Markel 1996[12] | 54 | 27 | Stage I -20.3%Stage II A– 59.2%Stage IIB– 12.9%Stage III -7.4% | HHS | NO | 11.1 | (% out of FICAT Pre-Op Sub-groups)Stage I -45.4%Stage II A–37.5 %Stage IIB–14.3 %Stage III -25%% | 11.1 (48.1%) |
| Miyahara 2018[54] | 30 | 6 | Stage I 37% Stage 2A 63% | Merle d’Aubigne and Postel  | Only partial improvement | n/a | 27% (22/30 have collapsed) | 6 (50%) |
| Mohanty 2016[55] | 33 | 24 | Stage I - 12.2%Stage IIA – 54.6%Stage IIB – 9%Stage III – 24.2% | HHS | Stage I- YESStage IIA – YESStage IIB – YESStage III – NO | n/a | 54.5 %- no progression | n/a (27%) |
| Sallam 2017[63] | 38 | 94 | Stage I: 10.5%Stage IIA: 44.7%Stage IIB: 18.4%Stage III: 26.3% | HHS | Stage I: 75%Stage IIA : 65%Stage IIB : 29%Stage III :5 0% | 51.8 | (% out of FICAT Pre-Op Sub-groups)Stage I: 50%Stage IIA:42.2%Stage II B: 28.6%Stage III:30% | 51.8 (38.2%) |
| Song 2007[65] | 163 | 87 | Stage I: 23.9%Stage IIA: 39.3%Stage IIB: 10.4%Stage III: 26.4% | HHS | N/a | 25.2 | (% out of FICAT Pre-Op Sub-groups):Stage I: 79.5%Stage IIA: 76.6%Stage IIB: 76.5%Stage III: 34.9% | 25.2 (30.6%) |
| Yoon 2000[70] | 39 | 61 | Stage I :43.5%Stage II:35.8%Stage III:20.5% | N/a | N/a | 48.7 | (% out of FICAT Pre-Op Sub-groups):Stage I :70.6%Stage II:35.8%Stage III: 0% | 18 (48.7%) |
| Nr – number of hips; Avg – average; THR – total hip replacement; n/a – not available; HHS – Harris Hip Score; VAS – visual analogue scale. |